Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma

The investigators will measure different cytokines in the sputum (interleukin ((IL))-3, granulocyte-macrophage colony-stimulating factor ((GM-CSF)), IL5, IL-13, IL-33, IL-4, IL-25 thymic stromal lymphopoietin ((TSLP)) and eotaxin-1 ) and in the blood to evaluate their ability to predict the response after 6 months and 1 year of treatment with a biologic treatment (anti-IgE, anti-IL5, anti-IL5R) in terms of reduction in exacerbations and corticosteroid use, improvement in Forced expiratory volume in the first second (FEV1) (+200ml), in asthma control (ACQ decrease \>0.5, ACT increase \>3), in asthma quality of life (increase in AQLQ score \> 0.5) and the effect on sputum and blood inflammation.

NCT Number	NCT04520165
Lead Sponsor	University of Liege
Conditions	Severe Asthma
Enrollment	52 participants
Start Date	2014-01-01
Primary Completion	2023-01-26 (estimated)
Study Completion	2025-08-31 (estimated)
Updated on ClinicalTrials.gov	2024-10-04